Proactive Investors - Run By Investors For Investors

4D Pharma bullish on progress of microbiome-based cancer research

4D's lead oncology product has demonstrated immune-stimulatory characteristics in pre-clinical models
doctor and patient
Microbiome-based treatment is what 4D is investigating

4D Pharma PLC (LON:DDDD) will present data today outlining how its microbiome-based cancer treatment might activate the body’s response to the disease.

The company’s lead oncology candidate is MRx0518, a strain of live bacteria extracted from human faecal samples that in pre-clinical models has shown it can stimulate the immune system.

Duncan Peyton, chief executive, will highlight aspects of the mode of action of MRx0518 at the Microbiome R&D and Business Collaboration Forum in Rotterdam. 

Specific component

4D has identified a specific component of the bacteria, flaA, that plays a key role in the activity of MRx0518 and the body's response to cancer. 

Peyton said: "This is a key step in the development of a true microbiome-derived pharmaceutical product for the treatment of cancer. 

"Understanding the mode of action of MRx0518, through the identification of a specific gene product and its interaction with a high profile human oncology target, gives greater insight into its potential applications and benefits to cancer patients.”

Plans are at an advanced stage to open clinical studies for MRx0518 in the UK and the US in the near future.

View full DDDD profile View Profile

4D Pharma Timeline

Newswire
June 10 2016

Related Articles

seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use